BPC-157 + TB-500 (10 mg + 10 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

One subcutaneous injection daily is the cadence for both the standard and the advanced approach; this compound is dosed every day rather than on a weekly schedule. At 10 mg/mL of total blend, every dose in the protocol falls between 5 and 15 units, so insulin syringes marked to 30 or 50 units read more accurately than a 100 unit barrel, particularly for the 5 unit and 6.7 unit draws in Weeks 1 to 4. Sites are rotated systematically across abdomen, lateral thigh, upper arm, and buttocks to avoid lipohypertrophy, and for a localized injury the injection is placed subcutaneously near the affected area, not into it, when anatomically appropriate. The advanced loading phase uses a higher TB-500 load during the first 2 to 4 weeks based on clinical monograph recommendations and consumes peptide supply faster, so vial quantities are planned accordingly.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: standard protocols open at 500 mcg of total blend daily, which is 250 mcg of each peptide, as tolerance is assessed.
• Weeks 3 to 4: the daily total steps up to 666 mcg, around 333 mcg of each peptide. Advanced protocols instead run a 1,500 mcg loading dose across Weeks 1 to 4 for a higher TB-500 load.
• Weeks 5 to 8: both approaches converge on a 1,000 mcg daily maintenance total, 500 mcg of each peptide.
• Beyond 8 weeks: some protocols cycle 3 months on followed by 6 weeks off rather than running continuously.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming or a direct stream onto the powder.
3. Gently swirl or roll until fully dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 14 days. At 10 mg/mL of total blend, 1 unit = 0.01 mL » 100 mcg of blend, which is 50 mcg of BPC-157 plus 50 mcg of TB-500, on a U-100 insulin syringe: 500 mcg = 5 units, 666 mcg = about 6.7 units, 1,000 mcg = 10 units, 1,500 mcg = 15 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light; use within 14 days.

• Avoid repeated freezing and thawing of the reconstituted solution.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Planning is based on a 4 to 8 week daily course at the 1,000 mcg maintenance total, which works out to 7 mg of blend per week.

Peptide Vials (BPC-157 + TB-500, 10 mg + 10 mg):

• Four weeks totals 28 mg (2 vials), six weeks totals 42 mg (3 vials), and eight weeks totals 56 mg, which is 3 vials of the 20 mg blend; an advanced course that loads at 1,500 mcg daily through Week 4 totals 70 mg and calls for 4 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes, one per day (U-100, 30 or 50 unit markings preferred).
• Four weeks: 28 syringes. Six weeks: 42 syringes. Eight weeks: 56 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 20 mg vial takes 2.0 mL, so one 10 mL bottle of bacteriostatic water covers 5 vials, enough for a full 8 week course.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 14 swabs per week.
• Eight weeks: 112 swabs, which is two 100 count boxes.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection and dispose of it in a sharps container; reconstituted blend is used within 14 days, so vial timing is matched to the dosing block.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation and maintain consistent absorption, and document the daily dose and site rotation to keep the record consistent.
• For localized tissue repair work, the injection is placed subcutaneously near the site of injury within anatomical reason rather than into the structure itself.
• Every dose in this protocol is a small draw at 10 mg/mL: 5 units in Weeks 1 to 2, about 6.7 units in Weeks 3 to 4, and 10 to 15 units thereafter. A 30 or 50 unit syringe improves readability at these volumes, and each unit carries 50 mcg of each peptide, so a miscount of 1 unit shifts both peptides at once.
• Advanced loading consumes supply faster than the standard escalation, adding roughly one extra vial across an 8 week course, so vial quantities are planned before the course begins rather than mid cycle.
• Regulatory Note: neither BPC-157 nor TB-500 is an approved drug for human therapeutic use; both are supplied for research purposes only and not for human consumption. Both peptides are prohibited in competitive sports by WADA.

How This Works

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth factor systems involved in tissue repair. TB-500 (Thymosin beta 4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft tissue recovery, which is the rationale for delivering both peptides from a single blended vial.

Benefits & Side Effects

Observations from the published record.

• Tissue repair: both peptides demonstrate wound healing, tendon repair, and anti-inflammatory properties in animal models.
• Gastrointestinal support: BPC-157 shows gastroprotective and ulcer healing effects in preclinical studies.
• Complementary mechanisms: BPC-157 works through angiogenesis, nitric oxide signaling, and growth factor systems, while TB-500 acts on actin polymerization and cell migration, so the blend targets repair from two directions at once.
• Safety profile: preclinical data indicate a wide safety margin for BPC-157, with no lethal dose reported up to about 20 mg/kg, and TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg.
• Possible side effects: occasional mild injection site reactions such as redness and itching, plus rare reports of transient dizziness or nausea.
• Evidence limits: long term human safety data remain limited for both peptides, and much of the supporting work is preclinical.

Lifestyle Factors

Complementary strategies for best outcomes.

• Adequate protein intake supplies the amino acid substrate for tissue synthesis and repair; the signal cannot build matrix without raw material.
• Pairing the course with an appropriate rehabilitation protocol matters for musculoskeletal injuries, since load progression determines what the repaired tissue is built for.
• Quality sleep and stress management support the recovery and healing response the protocol is meant to amplify.
• Hydration plus balanced micronutrient intake, notably vitamins C and D and zinc, supports connective tissue health and collagen cross linking.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and injection site with alcohol; allow to dry completely.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue (use 23 to 25 gauge, 5/8 inch needle).
3. Aspiration is unnecessary for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, lateral thigh, upper arm, buttocks) to avoid lipohypertrophy.
5. For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.

References

Source citations for further reading.

1. Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and neurotransmitter interactions (Biomedicines, 2022).
2. BPC 157 and standard angiogenic growth factors: GI tract healing and angiogenesis (Current Pharmaceutical Design, 2018).
3. Thymosin beta 4: roles in development, repair, and regeneration (Annals NY Academy of Sciences, 2007).
4. Thymosin beta 4: a multi-functional regenerative peptide (Expert Opinion on Biological Therapy, 2018).